Robert Q. Le

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome

Robert Q. Le, Liang Li, Weishi Yuan et al. · The Oncologist · 2018 · 882 citations · Full text

Life Sciences, Immunology, Pharmacology +16

FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy

Donna Przepiorka, Robert Q. Le, Alexei Ionan et al. · Clinical Cancer Research · 2022 · 55 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Favorable Outcomes in Patients Surviving 5 or More Years after Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies

Robert Q. Le, Margaret Bevans, Bipin N. Savani et al. · Biology of Blood and Marrow Transplantation · 2010 · 39 citations · Full text

Medicine, Hematology, Oncology +14

FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic Therapy

Robert Q. Le, Xin Wang, Hongfei Zhang et al. · The Oncologist · 2022 · 28 citations · Full text

Pharmacy, Pediatrics, Pharmacotherapy +7

Male survivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events

Priyanka A. Pophali, Jeffrey K. Klotz, Sawa Ito et al. · Experimental Hematology · 2013 · 26 citations · Full text

Medicine, Cardiology, Hematology +13